United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $501.39, for a total transaction of $4,763,205.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $162,672,475.77. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Trading Down 0.2%

NASDAQ UTHR opened at $497.27 on Friday. The stock has a market capitalization of $21.33 billion, a price-to-earnings ratio of 17.79, a PEG ratio of 2.50 and a beta of 0.56. The stock has a 50-day moving average of $516.53 and a 200 day moving average of $540.64. United Therapeutics Corporation has a twelve month low of $402.50 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $6.41 EPS. Equities analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several hedge funds have recently made changes to their positions in the company. Callan Family Office LLC purchased a new stake in shares of United Therapeutics during the second quarter worth approximately $1,217,000. Nicholas Investment Partners LP lifted its stake in United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after acquiring an additional 3,766 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in United Therapeutics during the 2nd quarter worth approximately $3,359,000. Havemeyer Place LP acquired a new position in United Therapeutics during the 4th quarter worth approximately $2,189,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $633,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research reports. Royal Bank Of Canada dropped their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.